Testing paradigm Initiating liquid and tissue comprehensive genomic profiling (CGP) simultaneously is the fastest and most efficient testing paradigm.1,2*

Capture a wide range of targetable alterations† 50% faster
than other options.2‡

SWIPE TO REVEAL FULL TABLE

Graph comparing tissue biopsy and liquid biopsy turnaround showing that ordering Tissue and Liquid CGP together allows for 100% of targetable alterations in 14 days.
Read the study

*Non-small cell lung cancer patients who are negative from a plasma specimen for EGFR exon 19 deletions, L858R, T790M, EGFR exon 20 insertions, ERBB2/HER2 activating mutations, and KRAS G12C should be reflexed to tissue biopsy testing using an FDA approved tumor tissue test, if feasible.3 Note that “tissue CGP,” known as Guardant360 TissueNext, and “liquid CGP," known as Guardant360, have not been cleared or approved by the FDA. For the complete intended use statement including companion diagnostic indications, please see Guardant360 CDx Technical Information.

†This chart utilizes percent target alterations found by liquid and tissue CGP testing from the European Journal of Cancer Cui et al study. Turnaround time is defined as 7 days for liquid biopsy and 14 days for tissue genotyping. This information is based on Guardant Health data on file.

‡Testing paradigms are for illustrative purposes only.

§Data shown for the targetable alterations assessed in the study.

||Patients who have a negative Guardant360 CDx test result for an indicated companion diagnostic biomarker should be reflexed to tissue biopsy testing using an FDA-approved tumor tissue test, if feasible. Guardant360 TissueNext has not been cleared or approved by the FDA. For the complete intended use statement including companion diagnostic indications for Guardant360 CDx, please see Guardant360 CDx Technical Information.

#Liquid and tissue testing may be initiated at the same time, but sample processing does not occur concurrently.

References: 1. Page RD, Drusbosky LM, Dada H, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(1):72-81. doi:10.1016/j.cllc.2021.10.001 2. Cui W, Milner-Watts C, O'Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 3. Guardant360® CDx Technical Information. Guardant Health, Inc. Palo Alto, CA. July 2021. 4. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Palo Alto, CA.